Multiple immunotherapies, such as chimeric antigen receptor (CAR)‐T cells, checkpoint inhibitors, cancer vaccines, and tumour‐infiltrating lymphocytes (TILs), all aim to promote CD8+ T‐cell responses.2 This evidence concerns the gene CD8A and neoplasm.